Archive for the Category ◊ Neuro / Neuromodulation ◊

• Friday, January 24th, 2014

Johnson & Johnson subsidiary Codman Neuro’s recall of its Trufill n-BCA liquid embolic system gets labeled as a Class I measure by the FDA. Codman Neuro, a division of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency’s highest-risk classification. The […]

• Wednesday, December 11th, 2013

American doctors have begun implanting a new deep-brain stimulation system by Medtronic Inc. that senses and records brain activity at the same time it delivers therapy to treat Parkinson’s symptoms, essential tremors and epilepsy, the company announced Thursday. The Activa PC+S deep-brain stimulation system may allow researchers to actually make the link to brain signals […]

• Thursday, December 05th, 2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord Neuromodulators MONMOUTH JUNCTION, N.J.–(BUSINESS WIRE)–TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance for expanded indications in marketing the AIGISRx N Antibacterial Envelope for use with spinal cord neuromodulators. This comes after the recent FDA clearance of the AIGISRx […]

• Wednesday, November 27th, 2013

Sitoa Global Announces Exclusive Letter of Intent With UC San Francisco, New Business Strategy and Corporate Restructuring HONG KONG, CHINA–(Marketwired – Nov 25, 2013) – Sitoa Global Inc. (“Sitoa Global”, or “the Company”) (OTCQB: STOA) announced today that it entered into an exclusive letter of intent (“LOI”) with the University of California, San Francisco (“UCSF”) […]

• Thursday, November 21st, 2013

“Virtual reality hands” – controlled by stroke survivors’ thoughts – could help them recover use of their hands and arms, according to a small study presented at the American Heart Association’s Scientific Sessions 2013. “Using a brain-computer interface, we’ve created an environment where people who may be too physically impaired to move can practice mental imagery to […]

• Monday, November 18th, 2013

The Food and Drug Administration on Thursday approved an implantable brain-stimulating device for patients with hard-to-treat epilepsy. The agency said it cleared Neuropace’s RNS Stimulator to reduce seizures in epilepsy patients who have not responded well to medications. The device is implanted in the skull beneath the scalp and attaches to one or two wires […]

• Friday, October 18th, 2013

St. Jude Medical Reports Third Quarter 2013 Results ST. PAUL, Minn.–(BUSINESS WIRE)–St. Jude Medical, Inc. (NYSE:STJ) today reported sales and net earnings for the third quarter ended September 28, 2013. Third quarter highlights: Net sales increased by approximately 3 percent on a currency neutral basis from the third quarter of 2012 Completed the acquisition of […]

• Thursday, October 10th, 2013

MIAMI, Oct. 7, 2013 /PRNewswire/ — Surgeons treating patients with degenerative disc disease may now use a new stand-alone intervertebral body fusion device recently cleared by the Food and Drug Administration. Manufactured by Binder Biomedical Inc., the device presents a complete anterior lumbar fixation system with a simple, one-step locking mechanism. Called LOGIC, the system is designed […]

• Monday, October 07th, 2013

Synergetics USA Inc. reported net income of $1.4 million in the fourth quarter ended July 31, down 26 percent from the same period last year due to weak activity in emerging markets. “Our international results were softer than anticipated, driven by ongoing weakness in our base business and lower contributions from emerging markets compared to last […]

• Friday, September 27th, 2013

Bioness Appoints Todd Cushman as President & CEO VALENCIA, Calif.–(BUSINESS WIRE)– Bioness Inc. today announced that its Board of Directors has named Todd Cushman as the company’s President and CEO in an effort to refine its strategy and reorganize the company’s core operations to better support its strategic growth opportunities. Cushman has been involved in […]